# US 2016/0256445 A1 · Dihydropyridinone mgat2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256445 A1
- Document ID: US20160256445A1
- Status: Published application
- Kind: A1
- Application number: 15/154,210
- Filed: 2016-05-13
- Published: 2016-09-08
- Earliest claimed: 2013-05-29
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Saleem Ahmad; Lidet A. Negash
- Web page: https://patentgrep.com/patent/US20160256445A1

## CPC

- C07D 211/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/4436: containing a heterocyclic ring having sulfur as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 211/78: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 211/86: Oxygen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of Formula 1, in combination simultaneously, separately or sequentially with one or more additional therapeutic agents, wherein the compound of Formula I is:
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein:
ring A is independently phenyl; wherein said phenyl is substituted with 0-1 R6 and 0-2 R7;
R1 is independently selected from: —(CH2)m—(C3-6 carbocycle substituted with 0-2 Rb and 0-2 Rg), wherein said hydrocarbon chain may be straight or branched, saturated or unsaturated;
R2 is independently selected from: C1-4 alkyl, C3-4 cycloalkyl, and C1-4 haloalkyl;
R3 is independently selected from: H, F, C1-4 alkyl and CN;
R4 is independently selected from: H, F, and C1-4 alkyl;
R3 and R4 may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;
R5 is independently selected from: C1-4 alkyl, C1-4 haloalkyl, N(C1-4 alkyl)2, —(CH2)m—C3-6 carbocycle;
R6 is, at each occurrence, independently selected from: halogen, C1-5 alkyl substituted with 0-2 Rh, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy,
—(CH2)m—C3-6 carbocycle, —(CH2)m—NRfRi, CN, ORi, SRi,
R7 is, at each occurrence, independently selected from: halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
alternatively, R6 and R7, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring;
Ra is, at each occurrence, independently selected from: halogen, OH, C1-5 alkoxy, C1-5 haloalkyl, C1-6 haloalkoxy, N(C1-4 alkyl)2, COOH, and —(CH2)n—Rc;
Rb is, at each occurrence, independently selected from: halogen, OH, C1-10 alkyl, C1-10 alkoxy, C1-10 haloalkyl, C1-10 haloalkoxy, C1-10 alkylthio, C1-10 haloalkylthio, N(C1-4 alkyl)2, —CONH(C4-20 alkyl), —CONH(C4-20 haloalkyl),
—O(CH2)sO(C1-6 alkyl), —O(CH2)sO(C1-6 haloalkyl), Rc, and —(CH2)n(O)t—(CH2)mRc;
Rc is, at each occurrence, independently selected from: C3-6 cycloalkyl substituted with 0-2 Rd C3-6 cycloalkenyl substituted with 0-2 Rd, —(CH2)n-(phenyl substituted with 0-3 Rd);
Rd is, at each occurrence, independently selected from: halogen, OH, CN, NO2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, tetrazolyl, OBn and phenyl;
Re is, at each occurrence, independently selected from: H, C1-8 haloalkyl, —(CH2)n—C3-6 carbocycle, CO(C1-4 alkyl), COBn, and a C1-12 hydrocarbon chain substituted with 0-1 C1-4 haloalkyl; wherein said hydrocarbon chain may be straight or branched, saturated or unsaturated;
Rf is, at each occurrence, independently selected from: H and C1-4 alkyl;
Rg and Rh are, at each occurrence, independently selected from: halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
Ri is, at each occurrence, independently selected from: C1-4 alkyl, C3-4 cycloalkyl and phenyl;
n, at each occurrence, is independently 0, 1 or 2;
m, at each occurrence, is independently 0, 1, 2, 3, or 4;
s, at each occurrence, is independently 1, 2, or 3; and
t, at each occurrence, is independently 0 or 1.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the additional therapeutic agents are selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

### Claim 13 (depends on 11)

The pharmaceutical composition according to claim 11, further comprising one or more additional therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

### Claim 14

A method for the treatment of a disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula 1, where said disorder is selected from: diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH), retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein (HDL), high low-density lipoprotein (LDL), non-cardiac ischemia, lipid disorders, or glaucoma, wherein the compound of Formula I is:
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein:
ring A is independently phenyl; wherein said phenyl is substituted with 0-1 R6 and 0-2 R7;
R1 is independently selected from: —(CH2)m—(C3-6 carbocycle substituted with 0-2 Rh and 0-2 Rg), wherein said hydrocarbon chain may be straight or branched, saturated or unsaturated;
R2 is independently selected from: C1-4 alkyl, C3-4 cycloalkyl, and C1-4 haloalkyl;
R3 is independently selected from: H, F, C1-4 alkyl and CN;
R4 is independently selected from: H, F, and C1-4 alkyl;
R3 and R4 may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;
R5 is independently selected from: C1-4 alkyl, C1-4 haloalkyl, N(C1-4 alkyl)2, —(CH2)m—C3-6 carbocycle;
R6 is, at each occurrence, independently selected from: halogen, C1-5 alkyl substituted with 0-2 Rh C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy,
—(CH2)m—C3-6 carbocycle, —(CH2)m—NRfRi, CN, ORi, SRi,
R7 is, at each occurrence, independently selected from: halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
alternatively, R6 and R7, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring;
Ra is, at each occurrence, independently selected from: halogen, OH, C1-5 alkoxy, C1-5 haloalkyl, C1-6 haloalkoxy, N(C1-4 alkyl)2, COOH, and —(CH2)n—Rc;
Rb is, at each occurrence, independently selected from: halogen, OH, C1-10 alkyl, C1-10 alkoxy, C1-10 haloalkyl, C1-10 haloalkoxy, C1-10 alkylthio, C1-10 haloalkylthio, N(C1-4 alkyl)2, —CONH(C4-20 alkyl), —CONH(C4-20 haloalkyl),
—O(CH2)sO(C1-6 alkyl), —O(CH2)sO(C1-6 haloalkyl), Rc, and —(CH2)n(O)t—(CH2)mRc;
Rc is, at each occurrence, independently selected from: C3-6 cycloalkyl substituted with 0-2 Rd C3-6 cycloalkenyl substituted with 0-2 Rd, —(CH2)m-(phenyl substituted with 0-3 Rd);
Rd is, at each occurrence, independently selected from: halogen, OH, CN, NO2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, tetrazolyl, OBn and phenyl;
Re is, at each occurrence, independently selected from: H, C1-8 haloalkyl, —(CH2)n—C3-6 carbocycle, CO(C1-4 alkyl), COBn, and a C1-12 hydrocarbon chain substituted with 0-1 C1-4 haloalkyl; wherein said hydrocarbon chain may be straight or branched, saturated or unsaturated;
Rf is, at each occurrence, independently selected from: H and C1-4 alkyl;
Rg and Rh are, at each occurrence, independently selected from: halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
Ri is, at each occurrence, independently selected from: C1-4 alkyl, C3-4 cycloalkyl and phenyl;
n, at each occurrence, is independently 0, 1 or 2;
m, at each occurrence, is independently 0, 1, 2, 3, or 4;
s, at each occurrence, is independently 1, 2, or 3; and
t, at each occurrence, is independently 0 or 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is selected from the group consisting of:
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is:

### Claim 17 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is:

### Claim 18 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is:

### Claim 19 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is:

### Claim 20 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is:

### Claim 21 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is:

### Claim 22 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is:

### Claim 23 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is:

### Claim 24 (depends on 14)

The method of claim 14, wherein the compound of Formula 1 is:
